A new publication dated October 3, 2026 reports a post hoc analysis titled "Hospitalization outcomes in adults with type 2 diabetes mellitus treated with once-weekly insulin efsitora versus once-daily basal insulins: A post hoc analysis of the QWINT-1 to -4 randomized trials." The paper appears in Diabetes Research and Clinical Practice.
The analysis examines data from the QWINT-1 through QWINT-4 randomized trials, comparing once-weekly insulin efsitora to once-daily basal insulins, a category that includes insulin degludec, an approved basal insulin. The publication is identified as a post hoc analysis, meaning it reviews previously collected trial data rather than presenting results from a newly designed study.
No specific findings, hospitalization rates, or comparative outcomes are included in the available event data. The listing confirms only the publication's title, journal, and date. Readers seeking details on hospitalization outcomes or comparative results should consult the full text through the source link provided.
This brief reports the existence and bibliographic details of the publication only. It does not characterize efficacy, safety, or clinical significance of insulin degludec or insulin efsitora based on this analysis. For general background on insulin degludec, readers can consult the compound overview.